Shopping Cart
- Remove All
- Your shopping cart is currently empty
LSD1/HDAC6-IN-2 (JBI-802) is an orally effective inhibitor targeting LSD1, HDAC6, and MAO-A, demonstrating IC50 values of 5 nM, 11 nM, and 5 nM, respectively. This compound effectively suppresses the growth of multiple myeloma cells, including MM.1S, MM.1R, and RPMI-8226. Additionally, LSD1/HDAC6-IN-2 is utilized for researching acute myeloid leukemia and lymphoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | LSD1/HDAC6-IN-2 (JBI-802) is an orally effective inhibitor targeting LSD1, HDAC6, and MAO-A, demonstrating IC50 values of 5 nM, 11 nM, and 5 nM, respectively. This compound effectively suppresses the growth of multiple myeloma cells, including MM.1S, MM.1R, and RPMI-8226. Additionally, LSD1/HDAC6-IN-2 is utilized for researching acute myeloid leukemia and lymphoma. |
Targets&IC50 | MAO-B:6600 nM, HDAC6:11 nM, MAO-A:5 nM |
In vitro | LSD1/HDAC6-IN-2 (JBI-802) exhibits growth inhibitory activity against multiple myeloma cells MM.1S, MM.1R, and RPMI-8226, with EC50 values of 2 nM, 6 nM, and 280 nM, respectively. |
In vivo | LSD1/HDAC6-IN-2 (JBI-802), administered orally at a dosage of 25 mg/kg once daily for 12 days, exhibits antitumor activity in a mouse model of multiple myeloma. |
Molecular Weight | 443.34 |
Formula | C21H23BrN4O2 |
Cas No. | 2982787-50-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.